Loading...
•
Jun 30, 2022
BioMarin Q2 2022 Earnings Report
BioMarin announced record revenues and increased full-year 2022 top and bottom-line guidance.
Key Takeaways
BioMarin announced record revenues in the second quarter of 2022, driven by strong growth of VOXZOGO and solid contributions from other franchises. Total revenues reached $533.8 million, a 6% increase compared to the same period in 2021. The company increased its full-year 2022 top and bottom-line guidance.
Total Revenues for the second quarter of 2022 were $533.8 million, an increase of 6% compared to the same period in 2021.
VOXZOGO commercial sales drove revenue growth due to new patients initiating therapy in Europe and the U.S.
GAAP Net Income and Non-GAAP Income increased by $14.8 million and $11.6 million, respectively, for the second quarter of 2022 compared to the same period in 2021.
BioMarin expects that ROCTAVIAN for the Treatment of Severe Hemophilia A Will Be Approved in Europe in the Third Quarter; Re-Submission of Biologics License Application (BLA) in the U.S. Planned for September 2022
Revenue by Segment
Forward Guidance
BioMarin increased full-year 2022 top and bottom-line guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...